Treatments and limitations for methicillin-resistant Staphylococcus aureus: A review of current literature

查看全文 作　　者：Rahul [1]Kashyap;Aditya [2]Shah;Taru [3]Dutt;Patrick M [4]Wieruszewski;Jaishid [5]Ahdal;Rishi [5]Jain 机构地区：[1]Department of Anesthesiology and Perioperative Medicine,Mayo Clinic,Rochester,MN 55902,United States;[2]Department of Infectious Diseases,Mayo Clinic,Rochester,MN 55902,United States;[3]Neurology Research,Mayo Clinic,Rochester,MN 55902,United States;[4]Department of Pharmacy,Critical Care Medicine,Mayo Clinic,Rochester,MN 55902,United States;[5]Workhardt Limited,Bandra East,Mumbai,Maharashtra 400051,India 出　　处：《World Journal of Clinical Infectious Diseases》索引2019年第9卷第1期,共10页 摘　　要：Methicillin-resistant Staphylococcus aureus(MRSA)has remained a major threat to healthcare;in both hospital and community settings over the past five decades.With the current use of antibiotics for a variety of infections,including MRSA,emerging resistance is a major concern.Currently available treatments have restrictions limiting their use.These issues include,but are not limited to,side effects,cross-resistance,lack of understanding of pharmacokinetics and clinical pharmacodynamics,gradual increment in minimal inhibitory concentration over the period(MIC creep)and ineffectiveness in dealing with bacterial biofilms.Despite availability of various therapeutic options for MRSA,the clinical cure rates remain low with high morbidity and mortality.Given these challenges with existing treatments,there is a need for development of novel agents for MRSA.Along with prompt infection control strategies and strict implementation of antibiotic stewardship,cautious use of newer anti-MRSA agents will be of utmost importance.This article reviews the treatments and limitations of MRSA management and highlights the future path. 关 键 词：METHICILLIN resistant METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ANTIBIOTICS MONOTHERAPY